Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma : a long-term retrospective analysis
Basagaña, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Martínez Rivera, Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Padró-Casas, Clara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Garcia-Olivé, Ignasi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Martínez-Colls, Mimar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Navarro, Juan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Pardo, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Cruz, Paula (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Cardona Peitx, Gloria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Carabias, Lídia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Roger, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Abad Capa, Jorge (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Rosell, Antoni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona. Departament de Medicina

Data:	2024
Resum:	Background: Some patients with severe asthma may benefit from treatment with biologics, but evidence has been mostly collected from randomized controlled trials (RCTs), in which patients' characteristics are different from those encountered in asthma patients in the real-world setting. The aim of this study was to describe the clinical features of complete responders versus non-complete responders to long-term treatment with biologics in patients with severe asthma attended in routine daily practice. Methods: Data of a cohort of 90 patients with severe asthma who were treated with biologics (omalizumab, benralizumab, and mepolizumab) for at least 12 months and were followed up to March 2022. Data recorded included clinical characteristics and effectiveness of treatment (exacerbation, Asthma Control Test [ACT] score, lung function, use of maintenance oral corticosteroids [mOCS]), FeNO, and blood eosinophils at baseline, at 12 months, and at the end of follow-up. Complete response is considered if, in addition to not presenting exacerbations or the use of mOCS, the ACT score was >20 and, the FEV >80% predicted. Results: An improvement in all asthma control parameters was observed after 12 months of treatment and a mean follow-up of 55 months. After 12 months of treatment 27. 2% of patients met the criteria of complete response and this percentage even increased to 35. 3% at the end of follow-up. Long-term complete response was associated to better lung function with mepolizumab and omalizumab treatment and to less previous exacerbations in the benralizumab group. The main cause of not achieving a complete response was the persistence of an airflow obstructive pattern. Conclusions: This study shows that omalizumab, benralizumab, and mepolizumab improved the clinical outcomes of patients with severe asthma in a clinic environment with similar effect sizes to RCTs in the long term follow-up. Airflow obstruction, however, was a predictor of a non-complete response to biologics.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Evere asthma ; Biologics ; Omalizumab ; Benralizumab ; Mepolizumab ; Retrospective analysis
Publicat a:	Annals of Medicine, Vol. 56, Núm. 1 (December 2024) , ISSN 1365-2060

DOI: 10.1080/07853890.2024.2317356
PMID: 38364218

13 p, 1.2 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats